3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
60
Prostatic Neoplasms
52
Squamous Cell Carcinoma of Head and Neck
43
Carcinoma, Non-Small-Cell Lung
39
Head and Neck Neoplasms
37
Lung Neoplasms
35
Lymphoma
34
Leukemia
22
Brain Neoplasms
20
Central Nervous System Neoplasms
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Glioblastoma
18
Uterine Cervical Neoplasms
17
Sarcoma
17
Rectal Neoplasms
17
Lymphoma, Follicular
16
Esophageal Squamous Cell Carcinoma
16
Esophageal Neoplasms
15
Lymphoma, Large B-Cell, Diffuse
14
Hodgkin Disease
14
Burkitt Lymphoma
14
Adenocarcinoma of Lung
13
Oligodendroglioma
12
Lymphoma, Non-Hodgkin
12
Neoplasm Metastasis
11
Astrocytoma
11
Rhabdomyosarcoma
10
Lymphoma, Large-Cell, Immunoblastic
10
Neuroblastoma
9
Nasopharyngeal Carcinoma
9
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Patient Preference
×
Radiotherapy
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts